Nephron pharmaceuticals corp received a report of a device malfunction from fda (b)(4) on (b)(6) 2014, that was reported as associated with the use of the ez breath atomizer.The maude report stated that the device ceases to function after multiple uses and is difficult to maintain.The maude report listed the event date as (b)(6) 2014 and the report date as (b)(6) 2014.During a follow-up phone call on (b)(6) 2014, the pt reported that the device became clogged after one week of use.He added that he used the product, because nephron's current asthmanefrin product reminded him of the asthma nefrin product sold with a glass atomizer when he was a child.The pt reported that he purchased the suspected product between the end of 2013 and the beginning of 2014.The pt did not experience any medical harm as a result of the malfunction.The pt is a (b)(6) year old male with a past medical history that is significant for asthma.He does not smoke, and he did not report any allergies to medications.
|
An evaluation of this failure mode from the design failure modes and effects analysis of this product, that the use of the product in a manner likely to cause adverse health consequence is improbable.Herewith the closure report as attachment, the root cause of this complaint cannot be identified since the unit would not be returned for further analysis.
|